InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.013 -0.197 (-93.81%)+
Announcement
Release
22 Aug 2025 9:17AM
Price at Release
$0.210
Full Release
download
Summary
Cynata Therapeutics Limited (ASX: CYP) announced it has entered into an At-the-Market Subscription Agreement (ATM Agreement) with Acuity Capital, providing the company with up to $4 million of standby equity capital. Under the arrangement, Cynata may issue shares at its sole discretion, at any time, at the prevailing market price, with no restrictions on timing or minimum subscription amounts. The ATM Agreement provides Cynata with flexible funding to support its operational and strategic objectives. The company also notes that, as security for the arrangement, it has agreed to issue 5 million ordinary shares to Acuity Capital, which can be repurchased or offset against future subscriptions under the agreement. There are no fees payable for the standby facility, other than standard legal costs and the granting of the security shares. This funding flexibility is designed to strengthen Cynata's balance sheet as it advances clinical trial programs and other corporate initiatives.
Key Points
  • Cynata Therapeutics Limited (CYP) has entered into an At-the-Market Subscription Agreement with Acuity Capital.
  • The agreement provides access to up to $4 million in standby equity capital.
  • Cynata can issue shares at its own discretion, at the prevailing market price, with no restrictions on timing or minimum subscription amount.
  • The ATM facility aims to provide flexible funding to support Cynata's operations and strategic goals.
  • Cynata will issue 5 million ordinary shares to Acuity Capital as security for the agreement.
  • These security shares can be repurchased or offset against future share subscriptions under the ATM facility.
  • There are no standby fees other than legal costs and the provision of security shares.
  • The arrangement is intended to strengthen Cynata’s balance sheet and support ongoing clinical programs and initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.